Drug Detail:Benralizumab (Benralizumab)
Drug Class: Interleukin inhibitors
Usual Adult Dose for Asthma
30 mg subcutaneously once every 4 weeks for the first 3 doses, then once every 8 weeks thereafter
Comments:
- This drug should be injected into the upper arm, thigh, or abdomen.
Use: For add-on maintenance therapy of patients with severe asthma with an eosinophilic phenotype
Usual Pediatric Dose for Asthma
12 years and older:
30 mg subcutaneously once every 4 weeks for the first 3 doses, then once every 8 weeks thereafter
Comments:
- This drug should be injected into the upper arm, thigh, or abdomen.
Use: For add-on maintenance therapy of patients 12 years and older with severe asthma with an eosinophilic phenotype
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
US BOXED WARNINGS:
- This drug should only be given by or under the supervision of a physician experienced in the use of potent antineoplastic drugs.
- Adequate clinical and laboratory facilities should be available to patients for proper monitoring of therapy.
CONTRAINDICATIONS:
- Hypersensitivity to the active component or any of the ingredients
Safety and efficacy have not been established in patients younger than 12 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- This drug should be administered by a healthcare professional.
- Administer this drug subcutaneously into the upper arm, thigh, or abdomen.
Storage requirements:
- Store the prefilled syringe in a refrigerator at 2C to 8C (36F to 46F) in the original carton to protect from light. Do not freeze. Do not shake.
Reconstitution/preparation techniques:
- The manufacturer product information should be consulted for product preparation prior to injection.
- Prior to administration, warm the syringe by leaving the carton at room temperature for about 30 minutes.
- Administer product within 24 hours or discard into sharps container.
General:
- This drug is indicated for the add-on maintenance therapy of patients with severe asthma with an eosinophilic phenotype. It is not indicated for other eosinophilic conditions. It is not indicated for the relief of acute bronchospasm or status asthmaticus.
Monitoring:
- Monitor patients after administration for hypersensitivity reactions.
Patient advice:
- Advise the patient to read the patient labeling.
- Inform patients that hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, rash) may occur, usually within hours of administration, but in some instances after days.
Frequently asked questions
- What type of asthma is Fasenra used to treat?
